Physician profile
Christopher Ng
NPI 1811424575
$531.32
in general payments reported to CMS, 2019-2025
11 companies · $69.88 in 2025
The $69.88 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.87 · 2022: $114 · 2023: $26.44 · 2024: $300 · 2025: $69.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $198.10 | 2022-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $79.99 | 2024-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $62.16 | 2019-2024 | |
| Pfizer INC. | $39.75 | 2022-2024 | |
| Ironshore Pharmaceuticals INC. | $39.12 | 2024 | |
| Glaxosmithkline, LLC. | $28.04 | 2022 | |
| Corium, LLC | $24.04 | 2024 | Azstarys |
| Verrica Pharmaceuticals INC. | $18.01 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $17.18 | 2024 | Flumist Quadrivalent |
| Nevro Corp. | $15.60 | 2022 | |
| Dynavax Technologies Corporation | $9.33 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.